The specter of generic challenges has repeatedly loomed above copyright’s famous drug, Sildenafil, raising questions about the prospects of related drug portfolios. While initial periods saw significant profits, the intellectual property lapse has created the door for cheaper substitutes, possibly reducing profitability and creating a significant